Description:
The Company is a specialized prenatal medical practice providing comprehensive maternal-fetal services focused on high-risk pregnancies. The Company offers advanced prenatal testing & screening, diagnostic procedures, genetic counseling & consultations, pregnancy-related diabetes management, and other monitoring & support services. The Company's care model is designed to proactively identify and manage pregnancy-related complications while helping patients navigate complex medical decisions with clarity and confidence.

Key Aspects:
• The Company's adjusted EBITDA grew at a compound annual growth rate (CAGR) of 17.5% from 2022 to the trailing-twelve-month (TTM) period ending June 30, 2025.
• The Company maintains a stable and diversified payor mix, averaging approximately 75% from commercial insurance, 20% from patient self-pay, and 5% from government programs.
• The Company maintains a Health Care Clinic Establishment Permit, enabling it to purchase, possess, and administer prescription medications under its FEIN rather than individual physician licenses, streamlining procurement and supporting operational efficiency.
• Management notes that the Company maintains agreements with local hospitals to provide perinatal care for unassigned patients admitted to each facility.
• The Company combines advanced obstetrical imaging with comprehensive perinatal and genetic consultation services, supporting risk assessment, diagnostic decision-making, and tailored pregnancy management, to enhance continuity of care for higher-risk patients.

Opportunities:
• Expand telemedicine capabilities to serve patients across neighboring states, increasing geographic reach, enhancing access to care in underserved markets, and growing the Company's overall patient base without significant physical footprint expansion.
• Strengthen referral relationships with OB/GYN groups and hospital systems by formalizing partnerships to enhance patient flow and revenue.
• Leverage newly implemented cloud-based systems to optimize scheduling, billing, and operational workflows.
• Implement AI-driven clinical tools to automate the review of blood glucose, blood pressure, and other remote patient monitoring data, improving provider efficiency and enhancing diagnostic accuracy in ultrasound imaging.
• Capitalize on recent demographic and clinical trends, including increasing maternal age and higher incidence of medically complex pregnancies, which require enhanced monitoring and specialist oversight, to support sustained long-term demand for maternal-fetal services.

Headquartered:
• Southeast US

Current Markets:
• The Company serves expectant mothers throughout its current state of operation, with a focus on patients experiencing high-risk or medically complex pregnancies requiring specialized maternal-fetal care.

Real Estate:
• The Company operates from seven facilities totaling 13,339 sq. ft. located throughout its current state of operation. All facilities are leased to the Company by unrelated third parties, with management noting that all leases are assumable by new ownership.

Shareholder Objectives:
• The Company is equally owned by two physicians via their respective professional associations (PAs). One owner is seeking retirement, while the other wishes to remain with the Company in their current role following a sale. The owner seeking retirement is willing to remain with the Company for a negotiable period to facilitate a smooth transition to new ownership.